Advertisement

Chemotherapy-Free Regimen Comparable to Rituximab-Chemotherapy as Front-Line Therapy for Follicular Lymphoma


Advertisement
Get Permission

IN PATIENTS with previously untreated advanced follicular lymphoma, the chemotherapy-free combination of rituximab (Rituxan) plus lenalidomide (Revlimid), the so-called R-squared (R2) regimen, yielded outcomes as good as those in patients who received standard rituximab-chemotherapy, in the interim analysis of the phase III RELEVANCE trial.1 The hope, however, was that the chemotherapy-free regimen would have been better. 

“At a median follow-up of 37.9 months, superiority for R2 over rituximab-chemotherapy was not established for both co-primary endpoints,” said Nathan Hale Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston. 


“At a median follow-up of 37.9 months, superiority for R2 over rituximab-chemotherapy was not established for both co-primary endpoints.”
— Nathan Hale Fowler, MD

Tweet this quote

The similar efficacy of R2 to rituximab-chemotherapy, however, positions this novel immunomodulatory approach as “a plausible new first-line option for patients with follicular lymphoma requiring treatment,” Dr. Fowler said at the 2018 ASCO Annual Meeting. 

The international open-label study compared the chemotherapy-free regimen with rituximab plus one of several chemotherapy choices. It is reportedly the first multicenter, international, open-label, randomized phase III trial of R2 vs rituximab-chemotherapy followed by rituximab maintenance in previously untreated patients with advanced follicular lymphoma requiring systemic treatment. 

RELEVANCE Details 

THE RELEVANCE trial enrolled 1,030 patients with primarily grade 1 or 2, high–tumor burden, newly diagnosed follicular lymphoma. Patients were randomized to receive rituximab-chemotherapy (regimen by physician’s choice) or R2. The co-primary endpoint was complete remission and complete remission unconfirmed at 120 weeks as well as progression-free survival. 

The R2 arm received rituximab for 6 cycles, continued in responders for 12 additional cycles, and lenalidomide for 6 to 12 cycles, continued in responders for a total of 18 cycles. The control arm included three possible regimens: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone), given to 72% of this arm; rituximab plus bendamustine (BR), given to 23%; or R-CVP (rituximab plus cyclophosphamide, vincristine, prednisone), given to 5%. This arm received the chemotherapy plus rituximab, followed by another 12 cycles of maintenance rituximab. The total treatment duration was 120 weeks. 

In the intent-to-treat analysis, by central review, complete remission and complete remission unconfirmed at 120 weeks was achieved in 48% of the R2 arm and 53% of the rituximab-chemotherapy arm (P = .13). The best overall response rate (which included partial responses) was 84% for R2 and 89% for rituximab-chemotherapy. Three-year progression-free survival was 77% and 78%, respectively (hazard ratio = 1.10; P = .48). Although overall survival is immature, 94% of patients in both arms were alive at 3 years, Dr. Fowler reported. 

The R2 and rituximab-chemotherapy regimens did reveal some different toxicities, although treatment discontinuations were similar between the arms and were mostly due to disease progression and toxicity. Patients who received rituximab-chemotherapy had more grade 3 or 4 neutropenia (31% vs 8%), febrile neutropenia (7% vs 2%), and use of growth factors (68% vs 23%) and more nausea, vomiting, neuropathy, and alopecia. Patients treated with R2 had more grade 3 or 4 cutaneous toxicity (7% vs 1%) and more tumor flare and diarrhea. 

DISCLOSURE: Dr. Fowler has served as a consultant or advisor to AbbVie, Celgene, and Merck and has received research funding from AbbVie, Celgene, Janssen, and Roche. 

REFERENCE 

1. Fowler NH, et al: RELEVANCE. 2018 ASCO Annual Meeting. Abstract 7500. Presented June 3, 2018. 


Related Articles

Expert Point of View: Bruce D. Cheson, MD

Bruce D. Cheson, MD

Bruce D. Cheson, MD

BRUCE D. CHESON, MD, Director of the Division of Hematology/Oncology at the Lombardi Comprehensive Cancer Center, Washington, DC, agreed that rituximab (Rituxan) plus lenalidomide (Revlimid; R2) is a reasonable first-line option, considering the findings of the...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.